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All fibrates are peroxisome proliferators-activated receptors (PPARs)-alpha agonists with ability to decrease
triglyceride and increase high density lipoprotein- cholesterol (HDL-C). However, bezafibrate has a unique
characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta) at comparable
doses. Therefore, bezafibrate operates as a pan-agonist for all three PPAR isoforms. Selective PPAR gamma agonists
(thiazolidinediones) are used to treat type 2 diabetes mellitus (T2DM). They improve insulin sensitivity by
up-regulating adipogenesis, decreasing free fatty acid levels, and reversing insulin resistance. However, selective
PPAR gamma agonists also cause water retention, weight gain, peripheral edema, and congestive heart failure. The
expression of PPAR beta/ delta in essentially all cell types and tissues (ubiquitous presence) suggests its potential
fundamental role in cellular biology. PPAR beta/ delta effects correlated with enhancement of fatty acid oxidation,
energy consumption and adaptive thermogenesis. Together, these data implicate PPAR beta/delta in fuel
combustion and suggest that pan-PPAR agonists that include a component of PPAR beta/delta activation might
offset some of the weight gain issues seen with selective PPAR gamma agonists, as was demonstrated by
bezafibrate studies. Suggestively, on the whole body level all PPARs acting as one orchestra and balanced
pan-PPAR activation seems as an especially attractive pharmacological goal. Conceptually, combined PPAR gamma
and alpha action can target simultaneously insulin resistance and atherogenic dyslipidemia, whereas PPAR beta/
delta properties may prevent the development of overweight. Bezafibrate, as all fibrates, significantly reduced
plasma triglycerides and increased HDL-C level (but considerably stronger than other major fibrates). Bezafibrate
significantly decreased prevalence of small, dense low density lipoproteins particles, remnants, induced
atherosclerotic plaque regression in thoracic and abdominal aorta and improved endothelial function. In addition,
bezafibrate has important fibrinogen-related properties and anti-inflammatory effects. In clinical trials bezafibrate
was highly effective for cardiovascular risk reduction in patients with metabolic syndrome and atherogenic
dyslipidemia. The principal differences between bezafibrate and other fibrates are related to effects on glucose level
and insulin resistance. Bezafibrate decreases blood glucose level, HbA1C, insulin resistance and reduces the
incidence of T2DM compared to placebo or other fibrates. Currently statins are the cornerstone of the treatment
and prevention of cardiovascular diseases related to atherosclerosis. However, despite the increasing use of statins
as monotherapy for low density lipoprotein- cholesterol (LDL-C) reduction, a significant residual cardiovascular risk is
still presented in patients with atherogenic dyslipidemia and insulin resistance, which is typical for T2DM and
metabolic syndrome. Recently, concerns were raised regarding the development of diabetes in statin-treated
patients. Combined bezafibrate/statin therapy is more effective in achieving a comprehensive lipid control and
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residual cardiovascular risk reduction. Based on the beneficial effects of pan-PPAR agonist bezafibrate on glucose
metabolism and prevention of new-onset diabetes, one could expect a neutralization of the adverse pro-diabetic
effect of statins using the strategy of a combined statin/fibrate therapy.
Keywords: Atherogenic dyslipidemia, Bezafibrate, Combined fibrate/statin therapy, Metabolic syndrome, PPAR,
Prevention, Residual cardiovascular risk, Type 2 diabetesConcept of the balanced pharmacological
pan-PPAR activation
All fibrates are peroxisome proliferators-activated recep-
tors (PPARs)-alpha agonists with ability to decrease trigly-
ceride and increase high density lipoprotein- cholesterol
(HDL-C). However, bezafibrate, in comparison with other
fibrates has a unique characteristic profile of action since
it activates all three PPAR subtypes (alpha, gamma and
delta) at comparable doses [1-5]. Therefore, bezafibrate
operates as a pan-agonist for all three PPAR isoforms
(Figure 1). Paradoxically, bezafibrate was serendipitously
developed before the discovery of PPARs, but till now is
the only clinically available pan-PPAR balanced ligand.
What is the main distinctiveness of the PPARs from a
clinical point of view?
PPAR alpha, activated by polyunsaturated fatty acids
and fibrates, is implicated in the regulation of lipid me-
tabolism, lipoprotein synthesis and metabolism, as well
as inflammatory response in liver and other tissues. PPAR
alpha plays a crucial role in regulating the β-oxidationFigure 1 Bezafibrate activates all three PPAR subtypes (alpha, gamma
pan-PPAR ligand.of fatty acids, a major source of cellular energy. Con-
sistent with this, PPAR alpha is highly expressed in tis-
sues with high fatty acid oxidation (like liver, kidney
and heart muscle), in which it controls a comprehensive
set of genes that regulate most aspects of lipid catabol-
ism. PPAR alpha activation increase HDL-C synthesis,
stimulates "reverse" cholesterol transport and reduces
triglycerides [6-8].
PPAR gamma regulates adipogenesis, lipid metabolism,
glucose control, and inflammation/vascular pathways.
Clinically, selective PPAR gamma agonists like thiazolidi-
nediones (glitazones) are used to treat type 2 diabetes
mellitus (T2DM). They improve insulin sensitivity by
up-regulating adipogenesis, decreasing free fatty acid
levels, and reversing insulin resistance. However, select-
ive PPAR gamma agonists also cause water retention,
weight gain, peripheral edema, and congestive heart fail-
ure. Such adverse effects may contribute to controversial
cardiovascular outcomes despite apparent improvements
in other risk factors [2,7,9,10].and delta) at comparable doses and operates as a balanced
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in clinical use (besides as a part of bezafibrate effects),
their role in the whole body level seems very important.
The expression of PPAR beta/delta in essentially all cell
types and tissues (ubiquitous presence) suggests its po-
tential fundamental role in cellular biology and possible
widespread effects of its agonists [11,12]. Particularly, se-
lective overexpression of a constitutively active form of
PPAR beta/delta in mouse adipose tissue induces signifi-
cant weight loss and protects against the obesity and
dyslipidemia induced by a high-fat diet [13]. This PPAR
beta/ delta effect correlated with enhancement of fatty
acid oxidation, energy consumption and adaptive thermo-
genesis. This change may explain why mice that over-
express PPAR beta/ delta in skeletal muscle can run
twice the distance of control mice [14]. Together, these
data implicate these PPAR in fuel combustion and sug-
gest that pan-PPAR agonists that include a component of
PPAR beta/delta activation might offset some of the
weight gain issues seen with selective PPAR gamma ago-
nists [15], as was demonstrated in bezafibrate studies [16].
The PPARs alpha and gamma are therapeutic targets
for hypertriglyceridemia and insulin resistance, respect-
ively. Evidence is now emerging that the PPARbeta/delta
isotype is a potential pharmacological target for the
treatment of disorders associated with metabolic syn-
drome. PPAR beta/delta activation increases lipid catab-
olism, improves the serum lipid profile and insulin
sensitivity in several animal models. In addition, PPAR
beta/delta ligands prevent weight gain and suppress
macrophage-derived inflammation. These data are
promising and indicate that PPAR beta/delta ligands
may become a therapeutic option for the treatment of
metabolic syndrome [17,18].
Suggestively, on the whole body level all PPARs acting
as one orchestra and balanced pan-PPAR activation seems
as an especially attractive pharmacological goal. Con-
ceptually, we were the first who proposed an idea of
pan-PPAR activation: combined PPAR gamma and alpha
action can target simultaneously insulin resistance and
atherogenic dyslipidemia [2,6], whereas PPAR beta/delta
properties may prevent the development of overweight
which typically accompanies selective PPAR gamma
ligands.
Balanced pan-PPAR activator bezafibrate: effects
in patients with atherogenic dyslipidemia and
metabolic syndrome
Hence, what data have we while looking on pan-PPAR
balanced activator bezafibrate? As all fibrates (PPAR
alpha activators), it significantly reduced plasma triglycer-
ides and increased HDL-C level (considerably stronger
than other major fibrates) [19-21]. Bezafibrate significant-
ly decreased the prevalence of small, dense LDL particles,remnants [22] and induced atherosclerotic plaque regres-
sion in thoracic and abdominal aortas [23]. In addition,
bezafibrate has important fibrinogen-related properties
and anti-inflammatory effects. It is well established that
fibrinogen is an independent predictor of cardiovascu-
lar events in patients with coronary artery disease [24].
Bezafibrate treatment lowers fibrinogen concentrations
and reduces other markers of systemic inflammation
(like tumor necrosis factor (TNF)-alpha and interleukin
(IL)-6 and C-reactive protein) [25-27]. As a result, en-
dothelial function was improved by bezafibrate [28-30]
but probably in a less extend than by high dose ator-
vastatin [31].
In clinical trials bezafibrate, as all fibrates, was highly
effective in patients with atherogenic dyslipidemia (pre-
sented by low HDL-C and increased triglycerides). In
patients without dyslipidemia this favorable effect was
absent and the same event rate was observed in both
bezafibrate and placebo groups. Consequently, the main
determinant for the overall results of the trial was main-
ly dependent on the number of the appropriately in-
cluded patients [19]. For example, in the Bezafibrate
Infarction Prvention (BIP) study about 50% of patients
did not need fibrates at all. In addition, significantly
more patients from the placebo group were “under cov-
ered” treated with statins (it was a violation of the study
protocol). As a result, after a mean 6.2 year follow-up
bezafibrate effect did not reach significance in the overall
population (9.4% risk reduction, p=0.24). However, in
appropriate patients with atherogenic dyslipidemia beza-
fibrate lead to 42% risk reduction (p=0.02) [19,20]. Fur-
thermore, after a mean 8.2 year follow-up bezafibrate
benefit was significant even in the overall population
(17% risk reduction, p=0.03) [32].
There are few direct “head to head” statin vs. bezafi-
brate comparisons in terms of cardiovascular outcomes.
Intermediate-size (274 patients) randomized controlled
trials have demonstrated that bezafibrate was signifi-
cantly better than pravastatin (a relatively weak statin) in
reduction of cardiovascular events [33].
Because pan-PPAR modulation is a key event in the
development of the metabolic syndrome [34], it was of
special interest to evaluate bezafibrate effects in this syn-
drome. In patients with metabolic syndrome, bezafibrate
treatment was associated with a significant (29%) re-
duced risk of any myocardial infarction (MI) and 33%
reduced risk of non-fatal MI. The early decrease in MI
incidence was reflected later in a tendency to reduced
cardiac mortality. Of note, among patients with augmen-
ted features of metabolic syndrome (4–5 risk factors for
metabolic syndrome) a marked 56% reduction in cardiac
mortality on bezafibrate was observed [16].
Figure 2 illustrates meta-analysis of all available 4
randomized control trials with bezafibrate (about 5000
Figure 2 Meta-analysis of all available 4 randomized control trials with bezafibrate [20,21,35,36] in “overall populations” (4946
patients), based in part on the comprehensive meta-analysis of Jun and colleagues [37]: 28% coronary events risk reduction was
observed (relative risk 0.722, confidence interval 0.518-1.005). This effect was significantly augmented (shown below the bold white line) in
the subgroups of appropriate patients with metabolic syndrome and dyslipidemia [19,20].
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part on the comprehensive meta-analysis of Jun and col-
leagues [37]: 28% coronary events risk reduction was
observed. As mentioned above, this effect was signifi-
cantly augmented in appropriate patients with metabolic
syndrome and dyslipidemia [19,20].
Balanced pan-PPAR activator bezafibrate: effects
on glucose metabolism and prevention of T2DM
The principal differences between bezafibrate and other
fibrates are related to its effects on glucose level and in-
sulin resistance. A large number of studies showed ben-
eficial effects of bezafibrate on glucose and insulin
metabolism [25,38-46]. These effects could be primarily
related to the direct influence of bezafibrate on insulin
sensitivity via PPAR gamma. However, additional PPAR
alpha – mediated effects on lipids metabolism may be
also important.
Hyperlipidemia, free fatty acids (FFAs) overload and
lipid accumulation in non-adipose tissues influence both
insulin action and insulin secretion and are frequently
associated with insulin resistance and the development
of T2DM [47-52]. We have previously shown that insu-
lin resistance is significantly correlated with triglycerides
level. Triglyceride-lowering and HDL-C–raising effects
of bezafibrate lead to decreased systemic availability of
fatty acids, diminished fatty acid uptake by muscle with
improvement of insulin sensitization, contributing alsoto a reduction of plasma glucose levels [40,42]. However
the role of FFAs extends beyond their ability to induce
or exacerbate insulin resistance and inflammation: they
may contribute directly to the deterioration of beta cell
function that accompanies the development of diabetes
[53-56]. Lipotoxicity and glucotoxicity share many com-
mon features, and FFAs and glucose metabolism are in-
timately linked through their ability to act as competing
oxidative substrates [48]. Probably, reducing the chronic
secretory demands for pancreatic beta-cell by improving
insulin sensitivity and direct reducing of triglycerides
and FFA accumulation in pancreatic islets can explain
preservation of beta cell function in patients with T2DM
treated with bezafibrate.
Bezafibrate has a modest but significant beneficial ef-
fect on HbA1C [41,43]. For example, in the recent large
Japanese the J-BENEFIT study HbA1c decreased signifi-
cantly by about −0.8% [43]. This effect was observed
irrespective of diabetes drug administration, but with a
strong positive relationship between triglyceride and
HbA1c reduction. In the BIP, bezafibrate reduces the in-
cidence and delays the onset of T2DM vs. placebo among
different high-risk populations: patients with impaired
fasting glucose (30% reduction) [44] and obese patients
even with normal fasting glucose levels (42% reduction)
[45]. A strong independent support for BIP was found in
a large British study of 16352 fibrate users during 5-year
follow-up: 12161 of patients used bezafibrate and 4191 of
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ciated with reduced hazard for diabetes of 41%; hazard
for progression to use of antidiabetic medication was by
46% less and progression to insulin by 22% less in pa-
tients with bezafibrate.
In contrast to patients treated with selective PPAR
gamma activators, there was no significant change in
mean body mass index (BMI) values in the bezafibrate
treated patients during the follow-up [19]. Probably, pre-
vention of weight gain could be explained by the PPAR
beta/delta mediated effects of bezafibrate. In addition,
bezafibrate significantly increased adiponectin levels both
in humans and rodents. This effect was mediated mostly
via PPAR alpha, but also partially via PPAR gamma [57].
Therefore, a pharmacological intervention that simulta-
neosly influences lipids and glucose metabolism can be
particularly effective to reduce the incidence and delay
the onset of T2DM in appropriate high risk patients.
These data support our suggestion that on the whole
body level a balanced synergism of all PPARs could be
justified.
Bezafibrate in combination with statin: current
concepts, evidences and suggestions
Currently statins are the cornerstone of the treatment
and prevention of cardiovascular diseases related to ath-
erosclerosis [58-60]. However, despite the increasing use
of statins as monotherapy for LDL-C reduction, a sig-
nificant residual cardiovascular risk is still present in
patients with atherogenic dyslipidemia and insulin resist-
ance which is typical for T2DM and metabolic syndrome
[61-71]. The risk associated with high triglycerides and
low HDL may be eliminated by bezafibrate. Among ma-
jor fibrates, bezafibrate appears to have the strongest
[42,47] effect on HDL-C.
Intensive statin therapy increases the possibility of side
effects (elevations of liver enzymes, muscle aches and
cognitive decline). Recently, concerns raised regarding
the development of diabetes in statin-treated patients.
Multiple studies showed that most popular statins - sim-
vastatin, atorvastatin, and rosuvastatin - have deleterious
effects on glycemic control [72-83]. For example, in the
CORONA trial [77], statin users were at a 1.13-fold
(95% CI, 0.86–1.50) greater risk of developing new-onset
diabetes than patients taking placebo. In the JUPITER
trial [78], the relative risk was even higher (1.25 [95% CI,
1.05–1.49]). In the SPARCL (Stroke Prevention by Ag-
gressive Reduction in Cholesterol Levels) trial [81], new-
onset T2DM developed in 166 of 1,905 patients rando-
mized to atorvastatin 80 mg/day and in 115 of 1,898
patients in the placebo group (8.71% vs. 6.06%, adjusted
HR: 1.37, 95% CI: 1.08 to 1.75, p = 0.011). It should be
pointed out that a newest statin – pitavastatin – seems
to be better in this issue in the post-hoc LIVES studysub-analysis [84]. Still, the cardiovascular benefits of sta-
tin therapy clearly outweigh the risk of developing dia-
betes [60,82]. However, the data suggest the need to
make patients aware of this possible risk and to monitor
patients for eventual development of diabetes, especially
on intensive-dose therapy. In addition, concerns regard-
ing new-onset diabetes should not be neglected due to
the serious economic burden which this condition pre-
sents now.
Of course, the importance of the intensive lifestyle
changes (diet, weight reduction and physical activity)
should be emphasized irrespective from the pharmaco-
logical interventions. However, as compared with statin
monotherapy (effective mainly on LDL-C levels and
plaque stabilization), the association of a statin with
bezafibrate will also have a major impact on triglycer-
ides, HDL and LDL particle size [20,22,58,85]. Moreover,
based on the beneficial effects of pan-PPAR agonist
bezafibrate on glucose metabolism and prevention of
new-onset diabetes (about 30-40% risk reduction), one
could expect neutralizing of the adverse pro-diabetic ef-
fect of statins (up to 25% increased risk). Therefore, a
combined bezafibrate/statin therapy will be more effect-
ive in achieving a comprehensive lipid control, residual
cardiovascular risk reduction and theoretically could
prevent statin induced new-onset diabetes.
Though muscle pain and myositis is an issue in statin/
fibrate treatment, adverse interaction appears to occur
to a significantly greater extent when gemfibrozil is ad-
ministered. Bezafibrate seems to be safer and better tol-
erated [86-96]. Particularly, plasma concentration of
statins are markedly increased by gemfibrozil but not by
bezafibrate [92]. However, safety concerns about gemfi-
brozil may lead to unjustified precautions regarding
bezafibrate administration and therefore diminish the
use of this useful agent.
The Multicentre double-blind The Fluvastatin Alone
and in Combination Treatment (FACT) study examined
the effects on plasma lipids and safety of a combina-
tion of fluvastatin and bezafibrate during 24 weeks in
333 patients with coronary artery disease and mixed
hyperlipidaemia [95]. Bezafibrate alone and fluvastatin+
bezafibrate combinations resulted in greater increases in
HDL-C and decreases in triglycerides compared with flu-
vastatin alone (P<0.001). Fluvastatin (40 mg)+bezafibrate
was the most effective for all lipid parameters with a de-
crease from baseline at endpoint in LDL-C of 24%, a de-
crease in triglycerides of 38% and an increase in HDL-C
of 22%. All treatments were well tolerated with no in-
crease in adverse events for bezafibrate-based combina-
tion therapy versus monotherapy. No clinically relevant
liver (aspartate aminotransferase [ASAT] or alanine ami-
notransferase [ALAT]) greater than three times the upper
limit of normal) or muscular (creatine phosphokinase
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laboratory abnormalities were reported.
The pooling data from 10 studies that included 1,018
patients treated with a combination of fluvastatin with
fibrate (bezafibrate 493 patients, fenofibrate 158 patients,
or gemfibrozil – 367 patients), have suggested that beza-
fibrate is the relatively safer fibrate for combination
treatment [96]. For these patients, the mean (very high)
dose of fluvastatin was 56 mg. The mean exposure was
38 weeks. Two patients (0.2%) treated with the com-
bined fluvastatin–fibrate therapy had a creatine kinase
level 10 times the upper limit of normal. One patient
was on a combination of fluvastatin 80 mg + gemfibrozil
1,200 mg, and the other patient was on fluvastatin 20 mg +
fenofibrate 200 mg. Bezafibrate, which was used 3 times
more than fenofibrate, was harmless in this analysis.
The safety and efficacy of combined bezafibrate-
simvastatin therapy was evaluated in 49 patients with
diet-resistant mixed hyperlipidaemia [93]. After a two-
month placebo phase, patients were randomized to re-
ceive either Bezafibrate Slow Release (SR) 400 mg or
simvastatin 20 mg followed by three months of combin-
ation therapy. Compared with simvastatin monotherapy,
the combined therapy induced further reductions in
triglycerides (by 26%, p = 0.0003) and apoB (by 11 mg/dl,
p = 0.03) and an increase in apoA1 (by 21 mg/dl,
p = 0.0008). Symptomatic and biochemical adverse events
did not occur more frequently on combined drug therapy
than on monotherapy. The combination of bezafibrate and
simvastatin was more effective in controlling mixed hyper-
lipidaemia than either drug alone and did not provoke more
adverse events. Despite of the strong theoretical back-
ground, there are few hard outcome data regarding com-
bined bezafibrate and statin treatment: only one small
randomized, controlled clinical trial and a number of the
observational studies. Gavish et al. [94] studied the efficacy
and safety of bezafibrate and simvastatin combination ther-
apy for diabetic dyslipidaemia. All patients (148) were on
single medication for a period of 6 months (100 on simvas-
tatin 20 mg day and 48 on bezafibrate SR 400 mg day), fol-
lowed by a period of 12 months on combined therapy for
all. The simvastatin and bezafibrate combination was found
to be more efficacious than a single medication for treat-
ment of diabetic dyslipidemia, as evidenced by improve-
ment in the lipoprotein profile, reductions in Lp(a) and
fibrinogen, and almost no clinically significant side-effects.
Side-effects included two patients who developed myopathy
when on the combined regimen and one on the single sta-
tin regimen. Plasma creatinine phosphokinase (CPK) levels
increased (but remained within the normal range) in most
of the patients on combination therapy. Most of the cardio-
vascular events occurred within the first 6 months of the
study, whilst the patients were on a single drug (12 events,
8.1%). There was a significant reduction in the event rateduring the year whilst the patients were on the combination
therapy (only two events – 1.4 %).
Recently, new data regarding statin/fibrate combina-
tion were published using the high quality comprehensive
nationwide Acute Coronary Syndrome Israeli Surveys
(ACSIS) registry [97]. There were 8545 patients treated
with statin alone and 437 patients treated with a statin/
fibrate combination (mainly bezafibrate). Development
of 30-day major acute coronary event (MACE) - primary
end-point - was recorded in 6.0% patients from the statin
monotherapy group vs. 3.2% from the combination group,
(p=0.01). The 30-day re-hospitalization rate was also sig-
nificantly lower in the combination group. Kaplan-Meier
analysis of total mortality during one year was close to
significance in favor of the combination (p=0.066). Multi-
variate analysis identified the fibrate/statin combination
as an independent predictor of 46% reduced risk of
MACE in overall population (p=0.03).
Madrid-Miller et al. in a small randomized controlled
trial [26] investigated the impact of the addition of beza-
fibrate to statin treatment in 50 patients with hyperfibri-
nogenemia and ST-elevation acute MI. Patients were
randomized into two groups (25 patients in each): beza-
fibrate 400 mg (group I) and conventional therapy
(group II). All patients were treated with statins. Primary
endpoint was decrease of fibrinogen concentrations. Sec-
ondary endpoints were recurrence of angina or infarction,
left ventricular failure and combined end points during
hospitalization. Fibrinogen concentrations were lower at
hospital discharge in group I than in group II (532.42 ±
129.6 vs. 889 ± 127.32 mg/dl in group II, p <0.0001). Sec-
ondary endpoints were more frequent in group II than in
group I: angina (56% vs. 4%, RR 0.071 [0.010-0.503], p
<0.0001), left ventricular failure (24% vs. 4%, RR 0.167
[0.022-1.286], p = 0.049) and combined endpoints (76%
vs. 8%, RR 0.105 [0.027-0.405], p <0.001). Therefore,
bezafibrate/statin treatment was a safe and was asso-
ciated with a lower incidence of MACE compared with
statins alone. Although in clinical trials the rate of ad-
verse events on combination was not significantly greater
compared with monotherapy, clinical and laboratory mo-
nitoring of patients who receive combined treatment
should be recommended.
Conclusions
The balanced pan-PPAR activator bezafibrate simultan-
eously targets atherogenic dyslipidemia and insulin re-
sistance without development of overweight; it reduces
plasma triglycerides and glucose levels, increases HDL-C
and decreases the prevalence of small, dense LDL parti-
cles. As a result of its concomitant effects on lipid and
glucose metabolism, bezafibrate reduces the incidence
and delays the onset of T2DM in high risk patients. In
patients with atherogenic dyslipidemia and/or metabolic
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reduced risk of cardiovascular events. Combined bezafi-
brate/statin therapy is more effective in achieving a com-
prehensive lipid control and residual cardiovascular risk
reduction. Based on the beneficial effects of this pan-
PPAR agonist on glucose metabolism and prevention of
new-onset diabetes, a neutralization of the adverse pro-
diabetic effects of statins by using a combined therapy
could be expected.
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